Adverse Events More Common with Off-Label Drug Use

He concluded, “The idea of trying to regulate off-label drug use based on these data seems misguided. If anything, these data support leaving doctors alone and letting doctors continue to make decisions in the best interest in their patients.”

Dr. Joshua M. Sharfstein, from Johns Hopkins Bloomberg School of Public Health, Baltimore, told Reuters Health by email, “The major issue with off-label use is that the FDA has not made a determination as to the balance of risks and benefits.”

The authors reported no funding or disclosures. The two commenters reported advising (unpaid) the FDA.

Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Handpicked Reviews of Contemporary Literature

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

Psoriatic Arthritis Drugs at a Glance, 2023

Psoriatic Arthritis Treatment Update

Reading Rheum

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Related Articles